Carisbamate in essential tremor: brief report of a proof of concept study.
Identifieur interne : 001911 ( PubMed/Corpus ); précédent : 001910; suivant : 001912Carisbamate in essential tremor: brief report of a proof of concept study.
Auteurs : Rodger J. Elble ; David M. Biondi ; Steve Ascher ; Frank Wiegand ; Joseph HulihanSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Anticonvulsants, Carbamates.
- drug therapy : Essential Tremor.
- Adolescent, Adult, Aged, Aged, 80 and over, Cross-Over Studies, Double-Blind Method, Female, Humans, Male, Middle Aged, Severity of Illness Index, Young Adult.
Abstract
The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.
DOI: 10.1002/mds.22872
PubMed: 20201005
Links to Exploration step
pubmed:20201005Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carisbamate in essential tremor: brief report of a proof of concept study.</title>
<author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name>
<affiliation><nlm:affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Biondi, David M" sort="Biondi, David M" uniqKey="Biondi D" first="David M" last="Biondi">David M. Biondi</name>
</author>
<author><name sortKey="Ascher, Steve" sort="Ascher, Steve" uniqKey="Ascher S" first="Steve" last="Ascher">Steve Ascher</name>
</author>
<author><name sortKey="Wiegand, Frank" sort="Wiegand, Frank" uniqKey="Wiegand F" first="Frank" last="Wiegand">Frank Wiegand</name>
</author>
<author><name sortKey="Hulihan, Joseph" sort="Hulihan, Joseph" uniqKey="Hulihan J" first="Joseph" last="Hulihan">Joseph Hulihan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="doi">10.1002/mds.22872</idno>
<idno type="RBID">pubmed:20201005</idno>
<idno type="pmid">20201005</idno>
<idno type="wicri:Area/PubMed/Corpus">001911</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Carisbamate in essential tremor: brief report of a proof of concept study.</title>
<author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name>
<affiliation><nlm:affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Biondi, David M" sort="Biondi, David M" uniqKey="Biondi D" first="David M" last="Biondi">David M. Biondi</name>
</author>
<author><name sortKey="Ascher, Steve" sort="Ascher, Steve" uniqKey="Ascher S" first="Steve" last="Ascher">Steve Ascher</name>
</author>
<author><name sortKey="Wiegand, Frank" sort="Wiegand, Frank" uniqKey="Wiegand F" first="Frank" last="Wiegand">Frank Wiegand</name>
</author>
<author><name sortKey="Hulihan, Joseph" sort="Hulihan, Joseph" uniqKey="Hulihan J" first="Joseph" last="Hulihan">Joseph Hulihan</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Anticonvulsants (therapeutic use)</term>
<term>Carbamates (therapeutic use)</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Essential Tremor (drug therapy)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term>
<term>Carbamates</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Essential Tremor</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Over Studies</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Severity of Illness Index</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">20201005</PMID>
<DateCreated><Year>2010</Year>
<Month>04</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>07</Month>
<Day>23</Day>
</DateCompleted>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>5</Issue>
<PubDate><Year>2010</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Carisbamate in essential tremor: brief report of a proof of concept study.</ArticleTitle>
<Pagination><MedlinePgn>634-8</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22872</ELocationID>
<Abstract><AbstractText>The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat analysis set; mean age 64 years; 66% men) received carisbamate 400 mg/day or matching placebo in a crossover study design with two 21-day treatment periods. The Fahn-Tolosa-Marín Tremor Rating Scale (TRS) was the primary assessment tool. Carisbamate and placebo treatment did not differ in their effect on the TRS (P = 0.94) or on measures of affect, mood, or quality of life. Carisbamate was generally well tolerated and had an adverse event profile comparable to that of placebo.</AbstractText>
<CopyrightInformation>(c) 2010 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elble</LastName>
<ForeName>Rodger J</ForeName>
<Initials>RJ</Initials>
<AffiliationInfo><Affiliation>Southern Illinois University School of Medicine, Springfield, Illinois 62794-9643, USA. relble@siumed.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Biondi</LastName>
<ForeName>David M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ascher</LastName>
<ForeName>Steve</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wiegand</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hulihan</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00524056</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002219">Carbamates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C518914">S-2-O-carbamoyl-1-o-chlorophenyl-ethanol</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D002219">Carbamates</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018592">Cross-Over Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020329">Essential Tremor</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2010</Year>
<Month>3</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>7</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22872</ArticleId>
<ArticleId IdType="pubmed">20201005</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001911 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001911 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:20201005 |texte= Carisbamate in essential tremor: brief report of a proof of concept study. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:20201005" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
![]() | This area was generated with Dilib version V0.6.23. | ![]() |